Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis

Morie A. Gertz, Martha Q. Lacy, John A. Lust, Philip R. Greipp, Thomas E. Witzig, Robert A. Kyle

Research output: Contribution to journalArticle

47 Scopus citations

Abstract

Primary systemic amyloidosis is the disorder that results from the deposition of insoluble immunoglobulin light chain fragments. Patients seen within 30 days of diagnosis have a median survival of 13 months. Patients treated with melphalan and prednisone have a median survival of 17 months. There is a need for new therapies. A prospective study was undertaken of high-dose dexamethasone in the treatment of 25 patients with previously untreated primary systemic amyloidosis. Treatment was similar to that given to patients with multiple myeloma. In this cohort, three patients showed objective regression with organ-specific improvement of the disease. The median survival of the entire group was 13.8 months. High-dose dexamethasone is of occasional benefit in patients with amyloidosis but does not appear to be superior to melphalan and prednisone chemotherapy.

Original languageEnglish (US)
Pages (from-to)104-109
Number of pages6
JournalMedical Oncology
Volume16
Issue number2
DOIs
StatePublished - Jul 1999

Keywords

  • Amyloidosis
  • Corticosteroid therapy
  • Dexamethasone therapy
  • Nephrotic syndrome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis'. Together they form a unique fingerprint.

  • Cite this